Indole-3-carbinol

Phase 3Small molecule

UUniversity of Kansas Medical Center

Indole-3-carbinol is one of 76 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

EndometriosisRecruiting

Prostate CancerPreclinical

Active, not recruiting

EndometriosisPhase 3

Recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

26 2

Opdivo

Bristol-Myers Squibb

Phase 3

22 3

Lupron

EEastern Cooperative Oncology Group

Phase 3

53 4

Tecentriq

Roche

Phase 3

8 5

Nizoral

WWim Janssens

Phase 3

21 6

Alinamin

Roche

Phase 3

6 7

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

14 8

Ritalin

Novartis

Phase 3

2 9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

4 10

Indole-3-carbinol

UUniversity of Kansas Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Endometriosis

NCT07164183

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Brassica Vegetables or Indole-3-Carbinol in Treating Patients With PSA Recurrence After Surgery for Prostate Cancer

Completed·VVanderbilt University·N/A·NCT00607932·66 enrolled

Cancer1 trial

Indole-3-Carbinol in Preventing Cancer in Healthy Participants

Completed·UUniversity of Kansas·Phase 1·NCT00100958

Breast Cancer1 trial

Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer

Completed·UUniversity of Kansas Medical Center·Phase 1·NCT00033345·17 enrolled

Endometriosis1 trial

Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis

Recruiting·AAlcea·Phase 3·NCT07164183·290 enrolled

Trial1 trial

Trial of Indole-3-Carbinol and Silibinin

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT03687073·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Indole-3-carbinol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Indole-3-carbinol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Indole-3-carbinol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Kansas Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Kansas Medical Center

Indole-3-carbinol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prostate Cancer1 trial

Cancer1 trial

Breast Cancer1 trial

Endometriosis1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News